Literature DB >> 20975551

Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system.

Peter Faybik1, Hubert Hetz, Gerfried Mitterer, Claus Georg Krenn, Judith Schiefer, Georg-Christian Funk, Andreas Bacher.   

Abstract

OBJECTIVE: Regional citrate anticoagulation has emerged as a promising method in critically ill patients at high risk of bleeding. However, in patients with liver failure, citrate accumulation may lead to acid-base and electrolyte imbalances, notably of calcium. The aim of this study was to evaluate the feasibility and safety of regional citrate anticoagulation during liver support using a molecular adsorbent recirculating system as well as its effects on electrolyte and acid-base balance in patients with liver failure.
DESIGN: Prospective observational study.
SETTING: University hospital. PATIENTS: Twenty critically ill patients supported by molecular adsorbent recirculating system resulting from liver failure between January 2007 and May 2009.
MEASUREMENTS AND MAIN RESULTS: The median duration of molecular adsorbent recirculating system treatment was 20 hrs (interquartile range, 18-22 hrs). Two of 77 molecular adsorbent recirculating system treatments (2%) were prematurely discontinued as a result of filter clotting and bleeding, respectively. The median citrate infusion rate, necessary to maintain the postfilter ionized calcium between 0.2 and 0.4 mmol/L, was 3.1 mmol/L (interquartile range, 2.3-4 mmol/L) blood flow. The median calcium chloride substitution rate was 0.9 mmol/L (0.3-1.7 mmol/L) dialysate. Total serum calcium remained stable during molecular adsorbent recirculating system treatments. There was a statistically significant increase of the ratio of total calcium to systemic ionized calcium (2.04 ± 0.32 mmol/L to 2.17 ± 0.35; p = .01), which reflected citrate accumulation resulting from liver failure. Under close monitoring, no clinically relevant electrolytes or acid-base disorders were observed.
CONCLUSIONS: Our results suggest that regional citrate anticoagulation is a safe and feasible method to maintain adequate circuit lifespan without increasing the risk of hemorrhagic complications while maintaining a normal acid-base as well as electrolyte balance in patients with liver failure supported by molecular adsorbent recirculating system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20975551     DOI: 10.1097/CCM.0b013e3181fee8a4

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  19 in total

Review 1.  Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy.

Authors:  Zhongheng Zhang; Ni Hongying
Journal:  Intensive Care Med       Date:  2011-11-29       Impact factor: 17.440

2.  Efficacy and safety of a citrate-based protocol for sustained low-efficiency dialysis in AKI using standard dialysis equipment.

Authors:  Enrico Fiaccadori; Giuseppe Regolisti; Carola Cademartiri; Aderville Cabassi; Edoardo Picetti; Maria Barbagallo; Tiziano Gherli; Giuseppe Castellano; Santo Morabito; Umberto Maggiore
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

3.  Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs.

Authors:  Ming Bai; Meilan Zhou; Lijie He; Feng Ma; Yangping Li; Yan Yu; Pengbo Wang; Li Li; Rui Jing; Lijuan Zhao; Shiren Sun
Journal:  Intensive Care Med       Date:  2015-12       Impact factor: 17.440

Review 4.  Regional citrate anticoagulation for renal replacement therapies in patients with acute kidney injury: a position statement of the Work Group "Renal Replacement Therapies in Critically Ill Patients" of the Italian Society of Nephrology.

Authors:  Enrico Fiaccadori; Valentina Pistolesi; Filippo Mariano; Elena Mancini; Giorgio Canepari; Paola Inguaggiato; Marco Pozzato; Santo Morabito
Journal:  J Nephrol       Date:  2015-01-14       Impact factor: 3.902

Review 5.  [Extracorporeal therapies in hepatic diseases].

Authors:  D Jarczak; G Braun; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-05-08       Impact factor: 0.840

Review 6.  [Extracorporeal therapy of patients with liver disease in the intensive care unit].

Authors:  V Fuhrmann; T Horvatits; A Drolz; K Rutter
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-27       Impact factor: 0.840

Review 7.  Regional citrate anticoagulation for RRTs in critically ill patients with AKI.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Enrico Fiaccadori
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

8.  A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System.

Authors:  Björn Meijers; Wim Laleman; Pieter Vermeersch; Frederik Nevens; Alexander Wilmer; Pieter Evenepoel
Journal:  Crit Care       Date:  2012-02-03       Impact factor: 9.097

9.  Regional citrate anticoagulation in patients with liver failure--time for a rethink?

Authors:  Sameer Patel; Julia Wendon
Journal:  Crit Care       Date:  2012-09-17       Impact factor: 9.097

10.  Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice.

Authors:  Heleen M Oudemans-van Straaten; Marlies Ostermann
Journal:  Crit Care       Date:  2012-12-07       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.